INT132717

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2005
Last Reported 2009
Negated 1
Speculated 1
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 1.27
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (PAX5) nucleus (PAX5) DNA binding (PAX5)
Anatomy Link Frequency
Urine 2
PAX5 (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 1 63.48 Quite High
Inflammation 5 38.16 Quite Low
abdominal pain 1 37.04 Quite Low
backache 2 22.64 Low Low
cva 9 5.00 Very Low Very Low Very Low
corticosteroid 8 5.00 Very Low Very Low Very Low
withdrawal 6 5.00 Very Low Very Low Very Low
Bioavailability 5 5.00 Very Low Very Low Very Low
Potency 5 5.00 Very Low Very Low Very Low
rheumatoid arthritis 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypercalcemia 21 100.00 Very High Very High Very High
Endometriosis (extended) 19 82.16 Quite High
Frailty 16 81.04 Quite High
Osteoporosis 128 78.24 Quite High
Disorder Of Lipid Metabolism 21 71.44 Quite High
Endometrial Cancer 7 69.08 Quite High
Fibrosis 1 63.48 Quite High
Postmenopausal Osteoporosis 21 62.64 Quite High
Disease 9 61.40 Quite High
INFLAMMATION 5 38.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pre- and post-treatment samples were analyzed for urinary excretion of deoxypyridinoline (DPD)/creatinine (Cr), a marker of bone resorption, and serum bone specific alkaline phosphatase (BSAP), a marker of bone formation.
Spec (analyzed) Localization (excretion) of BSAP associated with hypercalcemia
1) Confidence 0.50 Published 2005 Journal Int J Clin Pharmacol Res Section Abstract Doc Link 16402634 Disease Relevance 0.58 Pain Relevance 0
At the same time serum and urine samples were obtained for baseline measurement of markers of bone turnover (serum BSAP and urinary excretion of cross-linked n-terminal telopeptides of type 1 collagen).
Localization (excretion) of BSAP in urine
2) Confidence 0.47 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.12 Pain Relevance 0
Urine NTx, a marker of bone resorption, decreased by comparison with baseline by 73.4%, 71.3%, and 74.9% in the weekly, twice weekly, and daily groups while the equivalent decreases in BSAP were 40.1%, 41.7%, and 43.1%.
Localization (decreases) of BSAP in Urine associated with hypercalcemia
3) Confidence 0.44 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.38 Pain Relevance 0
There were no significant reported decreases in serum bone-specific alkaline phosphatase (BSAP) with 14 days of lasofoxifene treatment.
Neg (no) Localization (decreases) of BSAP
4) Confidence 0.06 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773750 Disease Relevance 0.20 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox